12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ImmunoPulse: Completed Phase II enrollment

OncoSec completed enrollment of 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma in an open-label, U.S. Phase II trial evaluating ImmunoPulse applied to up to 4 lesions on days 1, 5 and 8 at a maximum dose of 1.5 mg per cycle. At 12...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >